AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
3min chapter
Misconduct and the future of neurodegenerative disease research
The Top Line
Critical Examination of Antibody Treatments for Neurodegenerative Diseases
This chapter examines Prathena Biosciences' prazinezumab, an antibody treatment for Parkinson's disease, focusing on its trial history and the challenges faced, including previous trials yielding results indistinguishable from placebo. The chapter highlights concerns over the validity of the treatment and discusses the recommendation to halt ongoing research based on a thorough analysis of trial data.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode